Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.
about
Current Cervical Carcinoma Screening GuidelinesA comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme.Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample studyHPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflowsCervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in DenmarkThe BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening.Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays.Human Papillomavirus (HPV) virion induced cancer and subfertility, two sides of the same coin.Cervical cancer screening at crossroads.Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities.Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders.Performance of a new HPV and biomarker assay in the management of hrHPV positive women: Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer.Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women.Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus.High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
P2860
Q26799522-AE0BAD0F-AC94-4D4B-B2D8-C7BBFE5B20E3Q30276176-420FB3B5-027D-43E9-BF48-6399DA76D499Q34789131-79BE5B19-F077-47C7-8486-6026C1732D43Q35342179-F26EF489-D3F7-43FD-B729-BBF600B5B691Q35898888-F4F3CCC0-263E-4FEE-813A-D01C8759114EQ35988357-F8D4A7ED-0FC1-4888-BEBE-48CC43338854Q36066822-86F7D7AA-0682-4D75-A381-37EE34CBCF78Q36083187-FC7D15A2-CC36-4C11-B5AC-72CF78E2D668Q36205998-441383FF-E7B4-4C4F-940C-E72A02AA4AAAQ36750670-ACABBA02-545D-4B4B-928B-85FB60182389Q37218627-E7B42B2F-788A-49AE-B5AE-43103EF74D76Q37363392-487F4D20-4913-487F-A2C9-0CBFCEE4073EQ37637430-4454A363-2356-4A85-9482-E6AF2F8B12FFQ38232145-43726498-AC73-43B7-8467-11D814E0CC54Q39909954-32BF7E49-361E-442A-9783-DB06E8F604F4Q40043990-B6C522E0-DF64-48CF-92EE-F6967382F176Q40116201-E06A1DB1-F644-43F7-8C30-08D73078679BQ40440825-929625BA-4F6F-48E6-A99D-C14C93BD34AAQ42690821-9320CBCE-F1D2-460D-98A7-D4D376B754E8Q47315433-753E6F7D-9AF0-4EF7-B398-7F6BF102105AQ47580645-DE2C8334-876B-4E83-987F-9FC8D9BA07FB
P2860
Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Disagreement between human pap ...... in primary cervical screening.
@en
Disagreement between human pap ...... in primary cervical screening.
@nl
type
label
Disagreement between human pap ...... in primary cervical screening.
@en
Disagreement between human pap ...... in primary cervical screening.
@nl
prefLabel
Disagreement between human pap ...... in primary cervical screening.
@en
Disagreement between human pap ...... in primary cervical screening.
@nl
P2093
P2860
P50
P1433
P1476
Disagreement between human pap ...... in primary cervical screening.
@en
P2093
Carsten Rygaard
Ditte Møller Ejegod
Sarah Preisler
P2860
P304
P356
10.1371/JOURNAL.PONE.0086835
P407
P577
2014-01-20T00:00:00Z